| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lapatinib | CTRPv2 | pan-cancer | AAC | -0.0032 | 0.9 |
| mRNA | WZ8040 | CTRPv2 | pan-cancer | AAC | -0.0034 | 0.9 |
| mRNA | BRD-K33199242 | CTRPv2 | pan-cancer | AAC | -0.0033 | 0.9 |
| mRNA | RITA | CTRPv2 | pan-cancer | AAC | 0.0029 | 0.9 |
| mRNA | KU 0060648 | CTRPv2 | pan-cancer | AAC | 0.0028 | 0.9 |
| mRNA | BRD-A02303741 | CTRPv2 | pan-cancer | AAC | -0.0029 | 0.9 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0025 | 0.9 |
| mRNA | BRD-K79669418 | CTRPv2 | pan-cancer | AAC | 0.0035 | 0.9 |
| mRNA | BRD-K55473186 | CTRPv2 | pan-cancer | AAC | -0.0026 | 1 |
| mRNA | azacitidine | CTRPv2 | pan-cancer | AAC | 0.0019 | 1 |